Convalescent Plasma News and Research

RSS

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

Combination antibody therapies retain potency against SARS-CoV-2 variants, FDA / HHS research

Researchers in the United States have conducted a study showing that while variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can compromise the effectiveness of single therapeutic antibodies at preventing severe coronavirus disease 2019 (COVID-19), many combination antibody products remain potent against the variants.

21 Jul 2021

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Researchers in the United States have conducted a study suggesting that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit better neutralizing activity against variants of concern following vaccination against coronavirus disease 2019 (COVID-19) than previously uninfected vaccinees.

19 Jul 2021

Study sheds light on immune processes involved in long COVID

Researchers in the United States have provided important insights into the immune processes that may be associated with post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection – also referred to as long COVID (coronavirus disease 2019).

12 Jul 2021

Scientists study how our immune system responds to COVID-19 variants

Australian scientists researching how our immune system responds to COVID-19 have revealed that those infected by early variants in 2020 produced sustained antibodies, however, these antibodies are not as effective against contemporary variants of the virus.

8 Jul 2021

B.1.427/B.1.429 variant of SARS-CoV-2 evades neutralization via disulfide bond rearrangement

A new paper discusses an intriguing new mechanism of immune evasion traceable to specific mutations in the B.1.427/B.1.429 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

7 Jul 2021

New study reports low SARS-CoV-2 breakthrough infections in vaccinated healthcare workers

Researchers examined cases of SARS-CoV-2 infection in fully and partially vaccinated healthcare workers, finding that vaccination provided strong immunity to the virus even though VOCs are on the rise in the non-vaccinated community at large.

7 Jul 2021

Stool transplant may be worth exploring as treatment option for COVID-19

It might be worth exploring stool transplant to treat COVID-19 infection, suggest doctors in a letter published online in the journal Gut, after they used the procedure in two patients to prevent the recurrence of another bacterial infection.

2 Jul 2021

Antibody development against SARS-CoV-2 following Moderna vaccine

In a paper recently uploaded to the preprint server medRxiv* by Belda et al. (June 27th, 2021) two seroconversion panels containing the sera of individuals that received the Moderna (mRNA-1273) vaccine are compared, and the impact on neutralizing IgG antibody titers in these individuals is analyzed.

30 Jun 2021

H69/V70 deletion in Alpha variant enables SARS-CoV-2 to overcome chinks in its armor

One of the key mutations seen in the 'Alpha variant' of SARS-CoV-2 - the deletion of two amino acids, H69/V70 - enables the virus to overcome chinks in its armor as it evolves, say an international team of scientists.

29 Jun 2021

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

A new review of the emerging variants of concern (VOCs) of the SARS-CoV-2, which has caused the COVID-19 pandemic, shows that there is a major need to constantly re-evaluate the utility of existing therapeutics and vaccines against the virus and to develop new ones.

28 Jun 2021

Why SARS-CoV-2 delta variant is more infectious

German experts recently explained why the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant is more infectious and pathogenic than its ancestor. By conducting a series of in vitro experiments, they have revealed that increased ability to induce cell-to-cell fusion (syncytia) and reduced susceptibility to vaccine and infection-induced antibodies make the delta variant more infectious than previously circulating variants. The study is currently available on the bioRxiv* preprint server.

28 Jun 2021

A study on hospitalized COVID-19 patients who received plasma therapy

A new study has been published which focuses on the evaluation of the outcomes of infected COVID-19 patients who were treated with CCP therapy.

23 Jun 2021

Longitudinal study finds SARS-CoV-2 neutralizing antibodies decline a year after infection

Research led by Xin Zheng of Huazhong University of Science and Technology in Wuhan, China, found that about 90% of patients who recovered from COVID-19 continued to have IgG antibodies targeting the N-domain and receptor-binding domain of the spike protein. However, approximately 43% of patients showed signs of neutralizing antibody activity.

23 Jun 2021

GenScript and Duke-NUS announce notice of allowance for “Surrogate Virus Neutralization Technology”

GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading life sciences research and application service and product provider, and Duke-NUS Medical School, a premier, research intensive medical school, announced today that the U.S. Patent and Trade Office has issued a notice of allowance for the patent application for a novel Surrogate Virus Neutralization Technology (sVNT).

23 Jun 2021

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

A recent study discusses the findings of a study on patients with hematologic cancers who received convalescent plasma therapy following their diagnosis of COVID-19.

21 Jun 2021

Could horse-derived antibody therapy be effective against SARS-CoV-2 variants of concern?

A new study, released as a preprint on the bioRxiv* server, reveals the high neutralizing efficacy of hyperimmune horse serum against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could prove, if validated, to be a more affordable yet potent therapeutic in reducing the morbidity and mortality caused by this virus.

18 Jun 2021

Convalescent plasma associated with better survival in blood cancer patients with COVID-19

Convalescent plasma therapy was associated with better survival in blood cancer patients hospitalized with COVID-19, especially in sicker patients. The findings by the COVID-19 and Cancer Consortium (CCC19) are newly published in the peer-reviewed journal JAMA Oncology.

18 Jun 2021

Previous SARS-CoV-2 infection, vaccines provide protection against gamma variant, study finds

In early January 2021, travelers returning to Tokyo, Japan, from Amazonas, Brazil, were screened for COVID-19 at the airport. A few days later, the National Institute of Infectious Disease of Japan announced that the travelers had returned with a new variant of the SARS-CoV-2 virus.

18 Jun 2021

Convalescent plasma can improve chances of survival among blood cancer patients with COVID-19

A large, retrospective, multicenter study involving Washington University School of Medicine in St. Louis indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients hospitalized with the virus.

18 Jun 2021

Convalescent Plasma News and Research

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

Combination antibody therapies retain potency against SARS-CoV-2 variants, FDA / HHS research

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Study sheds light on immune processes involved in long COVID

Scientists study how our immune system responds to COVID-19 variants

B.1.427/B.1.429 variant of SARS-CoV-2 evades neutralization via disulfide bond rearrangement

New study reports low SARS-CoV-2 breakthrough infections in vaccinated healthcare workers

Stool transplant may be worth exploring as treatment option for COVID-19

Antibody development against SARS-CoV-2 following Moderna vaccine

H69/V70 deletion in Alpha variant enables SARS-CoV-2 to overcome chinks in its armor

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

Why SARS-CoV-2 delta variant is more infectious

A study on hospitalized COVID-19 patients who received plasma therapy

Longitudinal study finds SARS-CoV-2 neutralizing antibodies decline a year after infection

GenScript and Duke-NUS announce notice of allowance for “Surrogate Virus Neutralization Technology”

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

Could horse-derived antibody therapy be effective against SARS-CoV-2 variants of concern?

Convalescent plasma associated with better survival in blood cancer patients with COVID-19

Previous SARS-CoV-2 infection, vaccines provide protection against gamma variant, study finds

Convalescent plasma can improve chances of survival among blood cancer patients with COVID-19

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News